ABIVAX to Present Phase IIa Clinical Data on ABX464 during NIH/NIAID-Sponsored Strategies for an HIV Cure Meeting 2016

Paris, November 16th, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company is presenting clinical data on ABX464, ABIVAX’s first-in-class drug candidate for the treatment of patients with HIV/AIDS, during this week’s NIH / NIAID-sponsored Strategies for an HIV Cure Meeting 2016 in Bethesda, MD. ABIVAX’s presentation is entitled, “Antiviral activity and safety of ABX464".

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41